ArticleThe American journal of pathology1989
Formalin-resistant leukocyte surface antigens in the diagnosis of cutaneous malignant lymphomas.
Article in The American journal of pathology, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 8 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunophenotyping of routinely embedded lymphoma biopsies, increasingly used in nodal lymphomas, has not been systematically performed in cutaneous lymphomas. Eight monoclonal antibodies were tested directed against formalin resistant antigens (T cell biased: UCHL1, MT1; B cell biased: 4KB5, L26, Ki-B3; HLA-class II: CBL 120; activation antigens: Ber-H2; myeloid biased: Mac 387, M1) in cutaneous T (N = 29) and B (N = 10) cell lymphomas and pseudolymphomas (N = 9). UCHL1 and MT1 showed a high specificity and sensitivity. B cell-restricted antibodies L26 and 4KB5 showed the best sensitivity and specificity among the B cell-associated antibodies; Ki-B3 showed aberrant expression on T cells in some cases. Ber-H2 (CD30) was demonstrated in most cases of large cell anaplastic lymphoma and single cases of other lymphomas and lymphomatoid papulosis. Class II antigen expression, as determined by CBL 120, showed good specificity but low sensitivity, and antibodies directed against myeloid antigens did not react with tumor cells.
Indexed as
Identifiers
2774058PMC1880237W2219248758What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.